Skip to content

Scholar Rock SRRK EPS (Basic)

EPS (Basic) at other companies

Biogen logo
BiogenBIIB
$2.17+31.5%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$0.03-100%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-$0.40+14.9%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$0.53-1.9%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$0.84+4.5%
Arrowhead Research logo
Arrowhead ResearchARWR
-$0.93-133%

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%
Enterprise value$5.45B+82.6%
P/S170.9×

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's EPS (basic)?
Scholar Rock (SRRK) reported EPS (basic) of -$0.83 in Q1 2026.
How has Scholar Rock's EPS (basic) changed year-over-year?
Scholar Rock's EPS (basic) decreased by 23.9% year-over-year, from -$0.67 to -$0.83.
What is the long-term trend for Scholar Rock's EPS (basic)?
Over 4 years (2021 to 2025), Scholar Rock's EPS (basic) has grown at a -2.1% compound annual growth rate (CAGR), from -$3.59 to -$3.30.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.